Drug
Repaglinide clinical trials
Also written Prandin®.
- studies test it
- 43
- open now
- 3
- in phase 3
- 2
- first study started
- 2001
Keep track of what changes. Save the repaglinide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
43 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2001 | 4 |
| 2002 | 4 |
| 2003 | 4 |
| 2005 | 2 |
| 2006 | 4 |
| 2009 | 5 |
| 2012 | 2 |
| 2014 | 2 |
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 1
- Phase 3
- 2
- Phase 4
- 15
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 10
Novo Nordisk A/S (12) · Boehringer Ingelheim (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Novartis Pharmaceuticals (2) · Steno Diabetes Center Copenhagen (2) · Institut de Recherches Internationales Servier (I.R.I.S.) (1) · AstraZeneca (1) · Eli Lilly and Company (1)
Often tested with
Tested in the same studies.
Metformin (10) · Midazolam (7) · Rosuvastatin (6) · Bupropion (5) · Acarbose (3) · Omeprazole (2) · Atorvastatin (2) · Digoxin (2)
Studies
Open first, then newest update. How each study uses repaglinide is read from its arms, and is right about nine times in ten.
Testing it · 43
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruitingPhase 1Novartis PharmaceuticalsNCT07340190Written as repaglinide
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.RecruitingPhase 1PMV Pharmaceuticals, IncNCT07372625Written as repaglinide 0.5 mg tablet
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.Not yet recruitingPhase 1Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT06601517Written as Repaglinide
- A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the BloodCompletedPhase 1Boehringer IngelheimNCT06367153Written as Repaglinide
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsCompletedPhase 1Institut de Recherches Internationales Servier (I.R.I.S.)NCT07235748Written as Repaglinide
- A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT06494761Written as repaglinide
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06948747Written as Repaglinide
- A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06165146Written as Repaglinide
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06503679Written as Repaglinide
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedPhase 1Deciphera Pharmaceuticals, LLCNCT04530981Written as Repaglinide
- A Study of the Interaction of Other Drugs With TAK-279 in Healthy AdultsCompletedPhase 1TakedaNCT06290050Written as Repaglinide
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06196580Written as repaglinide; midazolam; SHR4640
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and DolutegravirCompletedPhase 1Novartis PharmaceuticalsNCT05236530Written as Repaglinide
- A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04457180Written as Repaglinide
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyCompletedPhase 4SanofiNCT03359837Written as Repaglinide
- Drug-drug Interaction of SHR3680 With Repaglinide and BupropionStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04664725Written as Repaglinide, Bupropion and SHR3680
- Treatment of Latent Autoimmune Diabetes of the AdultCompletedNot applicableNorwegian University of Science and TechnologyNCT01140438Written as metformin + sitagliptin +/- repaglinide
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)CompletedPhase 4Merck Sharp & Dohme LLCNCT01709305Written as Repaglinide
- Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 DiabetesCompletedPhase 2University of British ColumbiaNCT00451620Written as GlucoNorm
- Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisCompletedNot applicableArbelaez, Ana MariaNCT00763412Written as repaglinide
See all 43 studies that test repaglinide →
Given in every arm · 14 — repaglinide is usual care beside what is tested
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Repaglinide
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)RecruitingPhase 1/2Nuvalent Inc.NCT05384626Written as Repaglinide
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06092931Written as Repaglinide
- A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05444556Written as Repaglinide
- A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05469113Written as Repaglinide
- A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneCompletedPhase 1BiogenNCT04008186Written as Repaglinide 1 MG
- Voxelotor CYP and Transporter Cocktail Interaction StudyCompletedPhase 1PfizerNCT05981365Written as Repaglinide
- Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsCompletedPhase 1Epizyme, Inc.NCT03028103Written as Repaglinide
- A Drug Interaction Study of LY3871801 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05602675Written as Repaglinide
- A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05392127Written as Repaglinide Tablets
- Drug-drug Interaction Study of KL1333 in Healthy SubjectsCompletedPhase 1Abliva ABNCT04643249Written as Repaglinide
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedPhase 1Seagen Inc.NCT03723395Written as repaglinide
- Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory VariablesCompletedPhase 4University of PalermoNCT03824002Written as Repaglinide
- Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering DrugsCompletedPhase 4Novo Nordisk A/SNCT00819741Written as repaglinide
As the comparator · 3 — what is tested is compared with repaglinide
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanCompletedPhase 4University of LeicesterNCT02694263Written as Repaglinide
- Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 DiabetesCompletedPhase 4Novo Nordisk A/SNCT01465152Written as repaglinide
- Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy VolunteersCompletedPhase 1Novo Nordisk A/SNCT00959101Written as repaglinide
Codes
What other systems call repaglinide · ClinicalTrials.gg INT003605
- MeSH (NLM) C072379repaglinideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 668Z8C33LUREPAGLINIDEConfirmed FDA, NLM, Wikidata
- UNII (FDA) 85M30X62FMREPAGLINIDE, (-)-Confirmed NLM, Wikidata
- RxNorm 73044Confirmed FDA, Wikidata
- Wikidata Q2195995repaglinideConfirmed FDA, NLM, Wikidata
- Wikidata Q27269656(-)-repaglinideConfirmed NLM, Wikidata
- NCI Thesaurus C47703RepaglinideOne source FDA
- DrugBank DB00912One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C072379 | repaglinide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 668Z8C33LU | REPAGLINIDE | Confirmed FDA, NLM, Wikidata |
| UNII (FDA) | 85M30X62FM | REPAGLINIDE, (-)- | Confirmed NLM, Wikidata |
| RxNorm | 73044 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2195995 | repaglinide | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269656 | (-)-repaglinide | Confirmed NLM, Wikidata |
| NCI Thesaurus | C47703 | Repaglinide | One source FDA |
| DrugBank | DB00912 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.